Paras Healthcare IPO GMP 2026: Date, Share Price & Latest Updates

The Paras Healthcare IPO GMP (Grey Market Premium) is quoting at ₹25 as of Day 2 of bidding (October 22, 2026). Against the upper price band of ₹693, the unofficial grey market indicates an estimated paras healthcare share price on debut of ₹718, reflecting a modest expected listing gain of approximately 3.61%. The ₹1,450.00 crore book-built issue opened for bidding on Wednesday, October 21, and officially closes on Friday, October 23, 2026.

While the retail quota has already crossed full subscription (1.07x on Day 2), the broader paras healthcare gmp has cooled from an early high of ₹96 to ₹25 over the last 9 sessions. As hospital sector valuations face scrutiny, smart investors need to look past volatile grey market chatter and evaluate real unit economics, bed capacity, and debt balance sheets. At Pocketly, we break down the operational fundamentals, anchor commitments, and valuation multiples so you can make informed decisions without getting caught in market hype.

Quick Answer: Paras Healthcare IPO GMP & Key Issue Details

The Paras Healthcare IPO GMP trades at ₹25, indicating an estimated listing price of ₹718 (+3.61% listing gain) over the upper band of ₹693. The ₹1,450 crore issue comprises a fresh issue of ₹500 crore and an OFS of ₹950 crore. The minimum retail application is 1 lot (21 shares) requiring ₹14,553. The issue closes on October 23, 2026, with tentative listing on BSE and NSE scheduled for October 28, 2026.

Key Issue Details & Capital Structure

The ₹1,450.00 crore public offering from Paras Healthcare Limited combines fresh capital infusion for debt deleveraging alongside an Offer for Sale (OFS) by the promoter and private equity investor.

Tentative IPO Timetable

Keep track of the operational dates to ensure your UPI mandates and banking commitments are verified on time:

[Oct 21: Bidding Opens] ➔ [Oct 23: Issue Closes 5 PM] ➔ [Oct 26: Allotment Finalization] ➔ [Oct 27: Refunds & Demat Credit] ➔ [Oct 28: Exchange Listing]

• IPO Bidding Opens: Wednesday, October 21, 2026

• IPO Bidding Closes: Friday, October 23, 2026 (UPI mandate confirmation cutoff: 5:00 PM IST)

• Basis of Allotment: Monday, October 26, 2026

• Initiation of Refunds / Unblocking of ASBA Funds: Tuesday, October 27, 2026

• Credit of Equity Shares to Demat Accounts: Tuesday, October 27, 2026

• Tentative Listing Date: Wednesday, October 28, 2026

Day-Wise Paras Healthcare Daily GMP Trend

The paras healthcare ltd ipo gmp tracks informal, over-the-counter commitments prior to exchange listing. Over the 9-session observation window, the premium peaked at ₹96 (13.85%) before tapering down to ₹25 (3.61%) amid broader market volatility.

Retail Subject to Sauda: ₹400 per application

• Small HNI Subject to Sauda: ₹5,600 per application

• Trend Dynamics: Net change of -₹58 over 9 tracked sessions with 25% positive, 25% flat, and 50% negative session splits.

• Grey Market Advisory: The paras healthcare ipo gmp represents unofficial forward pricing negotiated between unregulated parties. It lacks clearing corporation guarantees, does not involve SEBI oversight, and can swing rapidly based on short-term market liquidity.

Day 2 Live Subscription Status

As of October 22, 2026 (11:39:57 AM), the paras healthcare ipo has achieved the following category-wise bidding traction:

Key Takeaway: Retail investors have fully subscribed their allotted 10% bucket (1.07x), whereas Qualified Institutional Buyers (QIBs) routinely place their major bids during the final hours of Day 3.

Lot Size & Capital Allocation Across Investor Categories

Bidders can structure their ticket size depending on their capital allocation strategy. Applications must be submitted in multiples of 21 shares:

Quota Allocation Breakdown:

• Qualified Institutional Buyers (QIB): 75.00% (1,56,92,640 shares, including 45% Anchor allocation)

• Non-Institutional Investors (NII/HNI): 15.00% (31,38,528 shares, split 2:1 between bNII and sNII)

• Retail Individual Investors (RII): 10.00% (20,92,352 shares, accommodating up to 99,635 allottees)

Anchor Book & Institutional Allocation

On Monday, October 19, 2026, Paras Healthcare successfully secured ₹652.50 crore from institutional anchor investors by allotting 94,15,584 equity shares at ₹693 per share.

• Anchor Lock-in Schedule:

1. 30-Day Lock-in (50% Shares): Wednesday, November 25, 2026.

2. 90-Day Lock-in (Remaining 50% Shares): Sunday, January 24, 2027.
   The anchor book offers institutional price validation at the upper cap of ₹693, providing baseline support against downside volatility.

Company Overview: Network & Growth Pipeline

Incorporated in 1987, Paras Healthcare Limited operates clinical specialty tertiary and quaternary healthcare centers across North India, Bihar, and Jharkhand under the renowned "Paras Health" brand.

• Current Scale: Operates 8 hospitals with an aggregate capacity of 2,211 beds across Gurugram, Panchkula, Patna, Darbhanga, Kanpur, Udaipur, Ranchi, and Srinagar (as of June 30, 2026).

• Clinical Focus (CONGOR): Specializes in Cardiac sciences, Oncology, Neurosciences, Gastro sciences, Orthopedics & sports injury, and Renal sciences. These high-acuity CONGOR specialties generated 75.30% of total hospital revenue in Fiscal 2026.

• Talent Base: As of March 31, 2026, the company employed 4,670 personnel, including 1,084 doctors and 1,937 nurses.

• Expansion Pipeline: Plans to add a 300-bed hospital in Gurugram and a 500-bed hospital in Ludhiana, expanding total capacity to 3,011 beds by March 2028.

Fundamental Review: Balance Sheet, Margins & Objects

Understanding the balance sheet is essential before taking an exposure. Paras Healthcare staged a significant turnaround in Fiscal 2026, moving from prior net losses to solid operational profitability.

Restated Consolidated Financials (₹ in Crores)

Key Performance Indicators (KPIs) & Operational Ratios

• Return on Equity (ROE): 11.83% (Q1 FY27 non-annualized), 12.98% (FY26).

• Return on Capital Employed (ROCE): 4.23% (Q1 FY27 non-annualized), 10.76% (FY26).

• Debt-to-Equity Ratio: 3.21x (as of June 30, 2026), elevated due to recent hospital additions in Kanpur and Srinagar.

• Net Asset Value (NAV): ₹44.06 per share (June 30, 2026).

• Price-to-Book (P/B): 15.73x based on Q1 FY27 NAV.

Objects of the Issue

The net fresh issue proceeds of ₹375.00 crore (out of ₹500 crore gross) are earmarked for:

1. Borrowing Prepayment/Repayment: ₹320.90 crore for clearing outstanding borrowings of the parent company.

2. Subsidiary Debt Repayment (PMHPL): ₹54.10 crore to repay/prepay borrowings of its Srinagar hospital operating subsidiary.

3. General Corporate Purposes: Residual capital to support operations.

Analyst Note: Retiring ₹375 crore of high-cost debt will reduce interest obligations significantly, providing an immediate boost to FY27 operating margins.

Peer Comparison & Valuation Analysis

Evaluating Paras Healthcare against recently listed hospital peers clarifies its risk-reward equation:

• Valuation Perspective: At the ₹693 upper band, the stock trades at an annualized post-issue P/E of 37.72x, which is attractively priced compared to large-cap hospital peers trading between 60x and 75x P/E multiples.

Paras Healthcare IPO Review: Is It Good or Bad?

Institutional broker recommendations stand at 5 Subscribe, 0 May Apply, 3 Neutral, and 0 Avoid. Here is the structural breakdown:

The Bull Case (Strengths):

1. Underpenetrated Geographic Focus: Paras operates as a leading tertiary care provider in regions like Bihar, Jharkhand, and parts of Haryana and Punjab, where quality bed supply per 1,000 residents remains well below the national average.

2. High-Margin Specialty Focus: With 75.3% of revenue driven by CONGOR specialties, Average Revenue Per Occupied Bed (ARPOB) continues to improve.

3. Aggressive Deleveraging: Allocating ₹375 crore to debt repayment will help bring down finance costs, freeing up operating cash flows.

The Bear Case (Risks):

1. Heavy OFS Component: Out of ₹1,450 crore, ₹950 crore constitutes secondary sales by the promoter (₹300 Cr) and Commelina Ltd. (₹650 Cr), meaning a major portion of IPO proceeds will not enter company operations.

2. Elevated Debt Load: Even post-repayment, total debt remains substantial at over ₹1,000 crore.

3. Soft Grey Market Demand: A falling paras healthcare gmp (down from ₹96 to ₹25) indicates lukewarm short-term speculative appetite.

Verdict: For long-term healthcare investors, the issue offers a sensibly valued healthcare platform at ~37.7x post-IPO P/E. However, short-term listing-gain traders should maintain realistic expectations, as a 3.61% GMP offers minimal buffer against broad market volatility.

Smart Money Liquidity: Managing Cash Flow During IPO Cycles

Active primary market participants know that bidding across multiple family accounts blocks substantial working capital:

• 1 Retail Lot blocks ₹14,553 via ASBA / UPI mandate.

• Applying across 5 family accounts to optimize retail allotment locks up ₹72,765.

• Applying for a Small HNI (sNII) quota blocks ₹2,03,742 for up to a week.

Navigating Short-Term Cash Mismatches

When capital is committed to ASBA mandates pending allotment finalization on October 26, unexpected household expenses, medical bills, or short-term obligations can trigger sudden liquidity crunches.

Rather than liquidating long-term equity investments or turning to informal, high-cost lenders, you can bridge temporary cash flow gaps smartly. At Pocketly, India's most trusted financial app used by 20M+ happy users, eligible applicants can access instant digital credit from ₹1,000 up to ₹50,000 with 100% paperless verification and rapid bank account disbursal.

If you are facing an unexpected expense while funds are locked in market applications:

• Apply for Instant Personal Loans, No CIBIL Score Needed at Pocketly to handle urgent financial shortfalls without collateral friction.

• For Working Professionals: Manage mid-month commitments smoothly before your salary arrives with our Personal Loan for Salaried applicants.

• For Self-Employed & Traders: Keep day-to-day cash flows steady using our Personal Loan for Self Employed options.

• For Students & Independent Earners: If you manage irregular earnings or stipends, explore our Loan for Non Salaried category.

Before borrowing, always evaluate your monthly cash outflows using our free Personal Loan EMI Calculator to ensure your repayments stay balanced. All credit facilities via Pocketly are extended by our RBI-registered NBFC partner, Speel Finance Company Private Limited, in strict alignment with our published Responsible Lending standards.

Trader Psychology & Risk Management Pitfalls

1. Never Confuse GMP with Guaranteed Listing Gains: The paras healthcare ipo gmp is an informal sentiment tracker, not an exchange-backed promise. If market indices turn volatile before October 28, a ₹25 premium can vanish before the opening bell.

2. Avoid Unregulated High-Interest Borrowing: Borrowing funds through informal channels to fund HNI subscriptions can result in severe financial stress if the listing pops marginally or allotment rates are low.

3. Monitor Your Fixed Obligation Ratio: Before taking on personal credit or locking funds in speculative bids, check your repayment capacity using our FOIR Calculator or budget your monthly surplus with our 50 30 20 Rule Calculator.

4. Beware of Multiple Bids Under a Single PAN: Submitting two separate applications under the same PAN within the retail category will cause automatic rejection by the registrar (MUFG Intime India).

Also Read: Jio Platforms IPO GMP : Today, Expected Share Price and What Indian Investors Should Know

Also Read: EAAA India Alternatives IPO GMP Holds at ₹0 Ahead of Bidding—Should Retail Investors Apply at ₹1,665?

Also Read: SFC Environmental Technologies IPO GMP Steady at ₹31: Should You Bid for a 9.39% Listing Pop?

Also Read: Before Bidding ₹15,000: 4 Key Things BLS Polymers IPO Financials & ₹35 GMP Reveal

Final Takeaway

The Paras Healthcare IPO presents an appealing regional hospital growth story with clear debt reduction plans and reasonable valuation multiples relative to historical peers. However, with the current Paras Healthcare IPO GMP holding at ₹25 (+3.61%), listing-gain seekers should exercise discipline, while long-term investors can evaluate post-listing operational performance as new hospital capacities come online in Gurugram and Ludhiana.

Ready to plan your personal finances and manage cash flows smoothly? 

👉 Check Your Eligibility With Pocketly

👉 Calculate Your Repayments with Our Personal Loan EMI Calculator

Frequently Asked Questions (FAQs)

1. What is the current Paras Healthcare IPO GMP today?

The paras healthcare ipo gmp is recorded at ₹25 as of October 22, 2026 (10:37 AM). Against the upper price band of ₹693, the estimated listing price stands at ₹718, projecting listing gains of roughly 3.61%.

2. What is the expected Paras Healthcare share price on listing day?

The expected paras healthcare share price based on current grey market trends is ₹718 (Upper Price Band of ₹693 + GMP of ₹25). Final listing day pricing on October 28, 2026, will depend on broader secondary market conditions and Day 3 QIB bidding momentum.

3. What are the opening and closing dates for the Paras Healthcare IPO?

The paras healthcare ipo opened for subscription on Wednesday, October 21, 2026, and will close on Friday, October 23, 2026, at 5:00 PM IST.

4. What is the lot size and minimum investment for retail investors?

The minimum lot size is 21 shares. At the upper price band of ₹693, the minimum investment amount required for a retail applicant is ₹14,553. Retail investors can bid for a maximum of 13 lots (273 shares) for ₹1,89,189.

5. What are the primary objects of the Paras Healthcare IPO?

Out of the ₹500 crore fresh issue proceeds, Paras Healthcare proposes to deploy ₹320.90 crore toward prepayment or repayment of company borrowings, ₹54.10 crore for debt repayment of its subsidiary PMHPL (Srinagar hospital), and the remaining balance for general corporate purposes.

6. Who is the registrar and lead manager for the Paras Healthcare IPO?

The registrar is MUFG Intime India Pvt. Ltd. The book running lead managers are JM Financial Ltd., BOFA Securities India Ltd., and Nuvama Wealth Management Ltd.

7. Is the Paras Healthcare IPO good or bad for retail investors?

From a fundamental standpoint, Paras Healthcare is well positioned in under-served North Indian markets with improving EBITDA margins (23.70% in Q1 FY27) and a reasonable post-IPO P/E of 37.72x. However, the high debt load and soft grey market premium (3.61%) mean investors seeking quick listing gains face limited short-term upside.

8. When will the Paras Healthcare IPO allotment status be finalized?

The basis of allotment is scheduled to be finalized on Monday, October 26, 2026. Refunds and unblocking of ASBA funds will take place on Tuesday, October 27, 2026, followed by demat credit of shares.

9. What should I do if my money is blocked in ASBA and I need urgent personal liquidity?

If your savings are temporarily blocked in IPO mandates and an unexpected expense occurs, apply for instant personal loans, no CIBIL score needed at Pocketly, trusted by 20M+ happy users. Eligible applicants can access quick, paperless personal credit up to ₹50,000 via our RBI-registered NBFC partner, Speel Finance Company Private Limited.

10. Does a positive GMP guarantee listing day profits?

No. The paras healthcare gmp represents informal dealer activity. Changing market sentiment, secondary market pullbacks, or global macro events can erase the premium prior to listing on October 28, 2026.